Literature DB >> 28927567

Discriminative Ability of Elixhauser's Comorbidity Measure is Superior to Other Comorbidity Scores for Inpatient Adverse Outcomes After Total Hip Arthroplasty.

Nathaniel T Ondeck1, Daniel D Bohl2, Patawut Bovonratwet1, Ryan P McLynn1, Jonathan J Cui1, Jonathan N Grauer1.   

Abstract

BACKGROUND: Identifying patients at highest risk for a complex perioperative course following total hip arthroplasty (THA) is more important than ever in order to educate patients, optimize outcomes, and to minimize cost and length of stay. There are no known studies comparing the clinically relevant discriminative ability of 3 commonly used comorbidity indices for adverse outcomes following THA: Elixhauser Comorbidity Measure (ECM), the Charlson Comorbidity Index (CCI), and the modified Frailty Index (mFI).
METHODS: Patients undergoing THA were extracted from the 2013 National Inpatient Sample. The discriminative ability of ECM, CCI, and mFI, as well as the demographic factors age, body mass index, and gender for the occurrence of index admission Centers for Medicare & Medicaid Services procedure-specific complication measures, extended length of hospital stay, and discharge to a facility were assessed using the area under the curve analysis from receiver operating characteristic curves.
RESULTS: ECM outperformed CCI and mFI for the occurrence of all 5 adverse outcomes. Age outperformed gender and obesity for the occurrence of all 5 adverse outcomes. ECM (the best performing comorbidity index) outperformed age (the best performing demographic factor) in discriminative ability for the occurrence of 3 of 5 adverse outcomes.
CONCLUSION: The less commonly used ECM outperformed the more often utilized CCI and newer mFI as well as demographic factors in correctly preoperatively identifying patients' probabilities of experiencing an adverse outcome suggesting that wider adoption of ECM should be considered in both identifying likelihoods of adverse patient outcomes and for research purposes in future studies.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Charlson Comorbidity Index; Elixhauser Comorbidity Measure; adverse outcomes; modified Frailty Index; total hip arthroplasty

Mesh:

Year:  2017        PMID: 28927567     DOI: 10.1016/j.arth.2017.08.032

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  20 in total

Review 1.  Review article: Patient characteristics that act as risk factors for intraoperative complications in hip, knee, and shoulder arthroplasties.

Authors:  Adel Hijazi; Muhammad Talha Padela; Zain Sayeed; Aws Hammad; Kamela Devole; Todd Frush; Gamal Mostafa; Walid K Yassir; Khaled J Saleh
Journal:  J Orthop       Date:  2019-06-17

Review 2.  [Risk management in orthopedic surgery : Stratification and adjustment of patient-individual risk factors].

Authors:  Matthias Meyer; Tobias Kappenschneider; Joachim Grifka; Markus Weber
Journal:  Orthopade       Date:  2022-01-07       Impact factor: 1.087

3.  The ability of comorbidity indices to predict mortality in an orthopedic setting: a systematic review.

Authors:  Per Hviid Gundtoft; Mari Jørstad; Julie Ladeby Erichsen; Hagen Schmal; Bjarke Viberg
Journal:  Syst Rev       Date:  2021-08-18

4.  Risk factors for venous thromboembolism following fractures isolated to the foot and ankle fracture.

Authors:  Michael J Gouzoulis; Peter Y Joo; Alexander J Kammien; William M McLaughlin; Brad Yoo; Jonathan N Grauer
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

5.  The Charlson and Elixhauser Scores Outperform the American Society of Anesthesiologists Score in Assessing 1-year Mortality Risk After Hip Fracture Surgery.

Authors:  Nathan H Varady; Stephen M Gillinov; Caleb M Yeung; Samuel S Rudisill; Antonia F Chen
Journal:  Clin Orthop Relat Res       Date:  2021-09-01       Impact factor: 4.755

6.  Short-Bowel Syndrome: Epidemiology, Hospitalization Trends, In-Hospital Mortality, and Healthcare Utilization.

Authors:  Mohamed Tausif Siddiqui; Wael Al-Yaman; Amandeep Singh; Donald F Kirby
Journal:  JPEN J Parenter Enteral Nutr       Date:  2020-12-17       Impact factor: 3.896

7.  Impact of comorbidity on the short- and medium-term risk of revision in total hip and knee arthroplasty.

Authors:  Jorge Arias-de la Torre; Kayla Smith; Alexandru Dregan; Jose M Valderas; Jonathan P Evans; Daniel Prieto-Alhambra; Luis Lozano; Antonio J Molina; Vicente Martín; Laia Domingo; Laura Muñoz; Mireia Espallargues
Journal:  BMC Musculoskelet Disord       Date:  2020-07-09       Impact factor: 2.362

8.  The Impact of Frailty on Short-Term Outcomes After Elective Hip and Knee Arthroplasty in Older Adults: A Systematic Review.

Authors:  Abigail M Schmucker; Nathaniel Hupert; Lisa A Mandl
Journal:  Geriatr Orthop Surg Rehabil       Date:  2019-05-06

9.  Anti-Tumour Necrosis Factor Therapy for Inflammatory Bowel Diseases Do Not Impact Serious Infections after Arthroplasty.

Authors:  Martin H Gregory; Andrew McKinnon; Dustin Stwalley; Kirk J Hippensteel; Edward V Loftus; Matthew A Ciorba; Margaret A Olsen; Parakkal Deepak
Journal:  J Crohns Colitis       Date:  2019-02-01       Impact factor: 9.071

Review 10.  The Update on Instruments Used for Evaluation of Comorbidities in Total Hip Arthroplasty.

Authors:  Łukasz Pulik; Michał Podgajny; Wiktor Kaczyński; Sylwia Sarzyńska; Paweł Łęgosz
Journal:  Indian J Orthop       Date:  2021-01-26       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.